Edwards Lifesciences Corp. completed the acquisition of Israel-based Valtech Cardio Ltd. for $340 million in stock and cash.

In addition, the deal provides for the potential of up to $350 million in prespecified milestone-driven payments over the next 10 years.

Valtech is the developer of the cardioband system for transcatheter repair of the mitral and tricuspid valves.